Download PDF
Geburtshilfe Frauenheilkd 2016; 76(05): 503-506
DOI: 10.1055/s-0042-102003
Aktuell diskutiert
Onkologie / Mammakarzinom
Georg Thieme Verlag KG Stuttgart · New York

Immuntherapien beim Mammakarzinom – Wie hängen Immunsystem und Krebs zusammen und woran arbeitet die Forschung?

Katrin Almstedt
,
Marcus Schmidt
Further Information

Publication History

Publication Date:
19 May 2016 (online)

Also available at
    Permissions and Reprints

Das Mammakarzinom stellt eine sehr heterogene Erkrankung dar. Zum aktuellen Zeitpunkt fungiert die St. Gallener Konsensusempfehlung der sogenannten intrinsischen Subtypen als Basis zur Erhebung molekular-biologischer prädiktiver und prognostischer Faktoren [1]. Weitere biologische Einflussgrößen, die als prognostische oder prädiktive Faktoren dienen könnten, werden im Rahmen von translationalen Arbeiten untersucht. Hier ist das Ziel, Übertherapien und unnötige Nebenwirkungen zu vermeiden und die Prognose zu verbessern. Neben genetischen Alterationen als Ursache für maligne Zelltransformationen gilt das Tumorstroma als zentrale Einflussgröße für maligne Prozesse und das Ansprechen auf onkologische Therapien. Ein besseres Verständnis über das Zusammenspiel zwischen dem primär gegen den Tumor wirkenden endogenen Immunsystem und bestehenden immunsuppressiven, tumorstimulierenden Mechanismen bietet die Möglichkeit zu neuen Therapieoptionen in der Behandlung des Mammakarzinoms.

 

  • Literatur

  • 1 Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013; 24: 2206-2223
    CrossrefPubMedGoogle Scholar
  • 2 Di Paola M, Angelini L, Bertolotti A et al. Host resistance in relation to survival in breast cancer. BMJ 1974; 4: 268-270
    CrossrefPubMedGoogle Scholar
  • 3 Schmidt M, Bohm D, von Torne C et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68: 5405-5413
    CrossrefPubMedGoogle Scholar
  • 4 Rody A, Holtrich U, Pusztai L et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. BCR 2009; 11: R15
    CrossrefPubMedGoogle Scholar
  • 5 Loi S, Sirtaine N, Piette F et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98. J Clin Oncol 2013; 31: 860-867
    CrossrefPubMedGoogle Scholar
  • 6 Adams S, Gray RJ, Demaria S et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32: 2959-2966
    CrossrefPubMedGoogle Scholar
  • 7 Ibrahim EM, Al-Foheidi ME, Al-Mansour MM et al. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Res Treat 2014; 148: 467-476
    CrossrefPubMedGoogle Scholar
  • 8 Loi S, Michiels S, Salgado R et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25: 1544-1550
    CrossrefPubMedGoogle Scholar
  • 9 Perez EA, Ballman KV, Tenner KS et al. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer. JAMA Oncol 2015; 1-9 DOI: 10.1001/jamaoncol.2015.3239.
    PubMedGoogle Scholar
  • 10 Denkert C, Loibl S, Noske A et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 105-113
    CrossrefPubMedGoogle Scholar
  • 11 Denkert C, von Minckwitz G, Brase JC et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33: 983-991
    CrossrefPubMedGoogle Scholar
  • 12 West NR, Milne K, Truong PT et al. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. BCR 2011; 13: R126
    CrossrefPubMedGoogle Scholar
  • 13 Ono M, Tsuda H, Shimizu C et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012; 132: 793-805
    CrossrefPubMedGoogle Scholar
  • 14 Yamaguchi R, Tanaka M, Yano A et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol 2012; 43: 1688-1694
    CrossrefPubMedGoogle Scholar
  • 15 Salgado R, Denkert C, Demaria S et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol 2015; 26: 259-271
    CrossrefPubMedGoogle Scholar
  • 16 Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England journal of medicine 2005; 353: 1673-1684
    CrossrefPubMedGoogle Scholar
  • 17 Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
    CrossrefPubMedGoogle Scholar
  • 18 Swain SM, Baselga J, Kim SB et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015; 372: 724-734
    CrossrefPubMedGoogle Scholar
  • 19 Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32
    CrossrefPubMedGoogle Scholar
  • 20 Schneeweiss A, Chia S, Hickish T et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 2013; 24: 2278-2284
    CrossrefPubMedGoogle Scholar
  • 21 Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015; 33: 1974-1982
    CrossrefPubMedGoogle Scholar
  • 22 Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704
    CrossrefPubMedGoogle Scholar
  • 23 Muenst S, Soysal SD, Gao F et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139: 667-676
    CrossrefPubMedGoogle Scholar
  • 24 Gatalica Z, Snyder C, Maney T et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23: 2965-2970
    CrossrefPubMedGoogle Scholar
  • 25 Wimberly H, Brown JR, Schalper K et al. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancer Immunol Res 2015; 3: 326-332
    CrossrefPubMedGoogle Scholar
  • 26 Schalper KA, Velcheti V, Carvajal D et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014; 20: 2773-2782
    CrossrefPubMedGoogle Scholar
  • 27 Mittendorf EA, Philips AV, Meric-Bernstam F et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res 2014; 2: 361-370
    CrossrefPubMedGoogle Scholar
  • 28 Nanda R, Chow LQ, Dees EC et al. Abstract S1–09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res 2015; 75 S1–109-S01–09
    PubMedGoogle Scholar
  • 29 Wolchok JD, Hoos A, O‘Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420
    CrossrefPubMedGoogle Scholar
  • 30 Mittendorf EA, Clifton GT, Holmes JP et al. Final report of the phase I / II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014; 25: 1735-1742
    CrossrefPubMedGoogle Scholar
  • 31 Martin SD, Coukos G, Holt RA et al. Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol 2015; 26: 2367-2374
    PubMedGoogle Scholar
  • 32 Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, NY) 2015; 348: 124-128
    CrossrefPubMedGoogle Scholar
  • 33 Kreiter S, Diken M, Selmi A et al. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol 2011; 23: 399-406
    CrossrefPubMedGoogle Scholar
  • 34 Kreiter S, Vormehr M, van de Roemer N et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 2015; 520: 692-696
    CrossrefPubMedGoogle Scholar